Research programme: oncolytic viral immunotherapies - Turnstone Biologics

Drug Profile

Research programme: oncolytic viral immunotherapies - Turnstone Biologics

Alternative Names: MG1-E6E7; MG1-Maraba virotherapy

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Turnstone Biologics
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 10 Oct 2017 AbbVie enters into an option license agreement with Turnstone Biologics for its oncolytic viral immunotherapies
  • 10 Oct 2017 Turnstone Biologics plans a phase I trial for human papillomavirus associated cancer, in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top